Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with Advanced HER2-Overexpressing or HER2-Mutated Non-Squamous Non-Small Cell Lung Cancer

-  Global phase 2 study will evaluate safety and efficacy of DS-8201 in patients with unresectable and/or metastatic non-squamous HER2-overexpressing or HER2-mutated non-small cell lung cancer -  Currently no therapy is specifically approved for HER2-overexpressing or HER2-m...

from PR Newswire: //https://ift.tt/2IZ3Jxk